Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ketamine for acute suicidal ideation
IRCT20220118053756N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ketamine in major depressive disorder (MDD) and suicidal ideation, sponsored by Iran University of Medical Sciences. Primary endpoint: Reduction in acute suicidal thoughts. Started Jan 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on IRCT20220118053756N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220118053756N1.